Codexis

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Codexis reports strong 2022 performance, eyes growth in Life Sciences

Codexis made significant progress in 2022, focusing on high-value programs and enhancing technical capabilities.
While facing challenges in managing expenses and revenue variability, the company is well-positioned with a strong cash position and growth opportunities.
Strategic collaborations and revenue diversification efforts position Codexis for sustainable growth and value creation in the future.

Codexis navigates revenue challenges, eyes growth through strategic partnerships

Codexis is strategically focusing on the ECO Synthesis platform and pharmaceutical manufacturing business for revenue growth and positive cash flow by 2026.
While facing challenges such as impairments on investments and revenue timing, the company is leveraging opportunities through partnerships and operational improvements.
The company's financial discipline, strong balance sheet, and key collaborations position it well for future growth and success in the pharmaceutical manufacturing sector.
With ongoing negotiations and advancements in technology, Codexis is poised for continued progress and innovation in the enzymatic solutions market.

Codexis reports robust Q4 performance, eyes growth through strategic partnerships

Codexis delivered a strong performance in Q4 2023, driven by strategic decisions, partnerships, and financial results showcasing growth potential.
The company's focus on expanding the ECO Synthesis platform and pharmaceutical manufacturing bodes well for sustained revenue growth.
While facing challenges in scaling operations and managing expenses, Codexis is well-positioned to capitalize on market opportunities and drive innovation.

Codexis projects 10% revenue growth, advances in RNA synthesis

Codexis is poised for growth in 2024, with a focus on revenue expansion, product innovation, and strategic partnerships to drive market success.
The company's strong performance in supplying enzymes for various programs underscores its market leadership and technological capabilities.
While facing challenges in diversifying its customer base and sustaining growth, Codexis is leveraging its strengths in technology and innovation to seize emerging opportunities.

Codexis reports Q3 revenue growth, eyes profitability amid strategic investments

Codexis navigates Q3 2024 with revenue growth in pharma manufacturing and strategic investments for future profitability.
Despite a net loss, the company maintains financial stability with a strong cash position and a focus on enhancing capabilities.
Challenges lie in achieving profitability by 2026, managing divestiture impacts, and optimizing gross margins amid operational changes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Total Revenue up 51% and Product Revenue up 135% YOY

Codexis Reports Second Quarter 2022 Financial Results

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for

Codexis, Inc. (NASDAQ: CDXS) has appointed Dr. Stephen Dilly, Board member, and biotechnology veteran, as President and CEO, effective August 9, 2022. After ten years of leading the transformation and growth of Codexis, the current President and CEO, John Nicols, will step down for.

Codexis Shares Slide On CEO Transition

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis

Codexis Announces CEO Transition Effective August 9, 2022

Codexis Inc (NASDAQ: CDXS) expects Q2 sales of approximately $38 million and FY22 sales of 135 million to $141 million, below the propr expectation of $152 million - $158 million. FY22 product revenues are expected to be $112 million - $118 million, consistent with prior.

Why Codexis Shares Are Slumping Today

Codexis Inc. CDXS shares fell in the extended session Thursday after the biotech company lowered its revenue forecast for the year and said that sales from Pfizer Inc. PFE would come in at the low end of an expected range. Codexis shares dropped more than 20% after hours, following a 4.7% decline in the regular session to close at $12.07.

Codexis stock drops as forecast comes in below Street estimate

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has entered into an agreement with Pfizer for the supply of a proprietary high-performance enzyme used to manufacture a critical intermediate for nirmatrelvir, an active pharmaceutical ingredient (API) in PAXLOVID™, Pfizer's antiviral therapeutic, which is currently authorized for emergency use by the U.S. Food and Drug Administration (“FDA”) for the treatment of mild-to-moderate COVID-19 in people at high risk of progression to severe illness and authorized or approved by other regulatory authorities across the globe.

Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)

Final financial results for the second quarter to be reported on August 4, 2022 Final financial results for the second quarter to be reported on August 4, 2022

Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?

Collaboration with Merck published in Science magazine

Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides

Codexis, Inc. (NASDAQ:CDXS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Nicols – President and Chief Executive Officer Ross Taylor – Senior Vice President and Chief Financial Officer Brendan Strong – Investor Relations, Argot Partners Conference Call Participants Steven Mah – Cowen Brandon Couillard – Jefferies Matthew Hewitt – Craig-Hallum Capital Group Evan Karev – Piper Sandler Operator Welcome to the Codexis First Quarter 2022, Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.

Codexis, Inc. (CDXS) CEO John Nicols on Q1 2022 Results - Earnings Call Transcript

Codexis (CDXS) delivered earnings and revenue surprises of 27.78% and 21.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates

Total Revenue up 96% and Product Revenue up 200% YOY; Product Gross Margin Expands to 72%

Codexis Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presentations highlighting three of the Company's gene therapy programs using directed evolution to potentially improve treatment options for Hemophilia A and lysosomal storage diseases at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, taking place from May 16 to May 19, 2022, in Washington, D.C. and virtually.

Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting

Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 39.6% in 4 Weeks, Here's Why the Trend Might Reverse for Codexis (CDXS)

REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the first quarter of 2022 on Thursday, May 5, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.

Codexis to Report First Quarter 2022 Financial Results on May 5

REDWOOD CITY, Calif. and BEVERLY, Mass.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the commercialization of seqWell's genomics workflow solutions. Codexis, a leading enzyme engineering company enabling the promise of synthetic biology, and seqWell, a developer of transformative library preparation products for demanding genomics applications, plan to collaborate on using Codexis' CodeEvo

Codexis and seqWell Announce Strategic Investment and Partnership Initiation

Codexis is a protein engineering company based in the United States that markets its products globally. The protein engineering industry is experiencing rapid growth as increased investment signals great potential for companies operating in the market.

Codexis: A Company Rooting Itself In A Blossoming Market

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42nd Annual Health Care Conference, being held virtually March 7-9, 2022.

Codexis to Participate in the Cowen 42nd Annual Health Care Conference

Codexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results - Earnings Call Transcript

Record Annual Total Revenue of $104.8M, Representing Eighth Consecutive Year of Revenue Growth

Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Earnings Preview: Codexis (CDXS) Q4 Earnings Expected to Decline

REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.

Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24

Codexis (CDXS) Surges 6.2%: Is This an Indication of Further Gains?

Codexis (CDXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Codexis Stock (CDXS)